Your browser doesn't support javascript.
loading
TWINGEN: protocol for an observational clinical biobank recall and biomarker cohort study to identify Finnish individuals with high risk of Alzheimer's disease.
Vuoksimaa, Eero; Saari, Toni T; Aaltonen, Aino; Aaltonen, Sari; Herukka, Sanna-Kaisa; Iso-Markku, Paula; Kokkola, Tarja; Kyttälä, Aija; Kärkkäinen, Sari; Liedes, Hilkka; Ollikainen, Miina; Palviainen, Teemu; Ruotsalainen, Ilona; Toivola, Auli; Urjansson, Mia; Vasankari, Tommi; Vähä-Ypyä, Henri; Forsberg, Markus M; Hiltunen, Mikko; Jalanko, Anu; Kälviäinen, Reetta; Kuopio, Teijo; Lähteenmäki, Jaakko; Nyberg, Pia; Männikkö, Minna; Serpi, Raisa; Siltanen, Sanna; Palotie, Aarno; Kaprio, Jaakko; Runz, Heiko; Julkunen, Valtteri.
Afiliação
  • Vuoksimaa E; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Saari TT; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland toni.saari@helsinki.fi.
  • Aaltonen A; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Aaltonen S; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Herukka SK; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Iso-Markku P; Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland.
  • Kokkola T; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Kyttälä A; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Kärkkäinen S; THL Biobank, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Liedes H; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Ollikainen M; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Palviainen T; VTT Technical Research Centre of Finland Ltd, Oulu, Finland.
  • Ruotsalainen I; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Toivola A; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
  • Urjansson M; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Vasankari T; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Vähä-Ypyä H; VTT Technical Research Centre of Finland Ltd, Espoo, Finland.
  • Forsberg MM; THL Biobank, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Hiltunen M; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Jalanko A; UKK Institute for Health Promotion Research, Tampere, Pirkanmaa, Finland.
  • Kälviäinen R; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Kuopio T; UKK Institute for Health Promotion Research, Tampere, Pirkanmaa, Finland.
  • Lähteenmäki J; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Nyberg P; VTT Technical Research Centre of Finland Ltd, Kuopio, Finland.
  • Männikkö M; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Serpi R; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Siltanen S; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Palotie A; Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland.
  • Kaprio J; Central Finland Biobank, Wellbeing Services County of Central Finland and University of Jyväskylä, Jyväskylä, Finland.
  • Runz H; VTT Technical Research Centre of Finland Ltd, Espoo, Finland.
  • Julkunen V; Biobank Borealis of Northern Finland, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, Oulu, Finland.
BMJ Open ; 14(6): e081947, 2024 Jun 12.
Article em En | MEDLINE | ID: mdl-38866570
ABSTRACT

INTRODUCTION:

A better understanding of the earliest stages of Alzheimer's disease (AD) could expedite the development or administration of treatments. Large population biobanks hold the promise to identify individuals at an elevated risk of AD and related dementias based on health registry information. Here, we establish the protocol for an observational clinical recall and biomarker study called TWINGEN with the aim to identify individuals at high risk of AD by assessing cognition, health and AD-related biomarkers. Suitable candidates were identified and invited to participate in the new study among THL Biobank donors according to TWINGEN study criteria. METHODS AND

ANALYSIS:

A multi-centre study (n=800) to obtain blood-based biomarkers, telephone-administered and web-based memory and cognitive parameters, questionnaire information on lifestyle, health and psychological factors, and accelerometer data for measures of physical activity, sedentary behaviour and sleep. A subcohort is being asked to participate in an in-person neuropsychological assessment (n=200) and wear an Oura ring (n=50). All participants in the TWINGEN study have genome-wide genotyping data and up to 48 years of follow-up data from the population-based older Finnish Twin Cohort (FTC) study of the University of Helsinki. The data collected in TWINGEN will be returned to THL Biobank from where it can later be requested for other biobank studies such as FinnGen that supported TWINGEN. ETHICS AND DISSEMINATION This recall study consists of FTC/THL Biobank/FinnGen participants whose data were acquired in accordance with the Finnish Biobank Act. The recruitment protocols followed the biobank protocols approved by Finnish Medicines Agency. The TWINGEN study plan was approved by the Ethics Committee of Hospital District of Helsinki and Uusimaa (number 16831/2022). THL Biobank approved the research plan with the permission no THLBB2022_83.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Bancos de Espécimes Biológicos / Doença de Alzheimer Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Bancos de Espécimes Biológicos / Doença de Alzheimer Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2024 Tipo de documento: Article